Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was conducted to see before and after treatment whether it provided improvement in the patient's clinical symptoms.
This research is the first to be conducted with preliminary research on humans.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Group | Experimental | Loratadine 10 mg/day and Fluticasone Furoate 27.5 mcg twice daily. |
|
| Treatment A: Quercetin 100 mg | Experimental | Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 100 mg/day. |
|
| High-Dose Quercetin | Experimental | Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 200 mg/day. |
|
| Apple Extract Only | Experimental | Apple fruit extract (Malus sylvestris Mill) and Quercetin 200 mg/day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quercetin | Other | In the treatment group, standard therapy is given along with additional quercetin at different doses. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total Nasal Symptom Score (TNSS) | The TNSS evaluates the severity of four nasal symptoms: nasal congestion, sneezing, nasal itching, and rhinorrhea. Each symptom is rated on a 4-point scale: 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total score is the sum of the four individual symptom scores, ranging from 0 to 12. Higher scores indicate worse symptom severity. | Baseline, Month 3, and Month 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Serum Interleukin-6 (IL-6) Levels | Concentration of IL-6 measured using Enzyme-Linked Immunosorbent Assay (ELISA). | Baseline, Month 3, and Month 6 |
| Malondialdehyde (MDA) Levels | Oxidative stress marker measured using ELISA kit. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
age 18 - 60 years
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitas Sebelas Maret Hospital | Surakarta | Central Java | 57126 | Indonesia |
Not provided
| Label | URL |
|---|---|
| protocol research | View source |
| ID | Type | URL | Comment |
|---|---|---|---|
| Niken Dyah Aryani K,MD,ORL-HNS | Individual Participant Data Set | View IPD |
This research is related to the results of the dissertation as a requirement for graduating from a doctoral degree
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 20, 2026 | Jan 26, 2026 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D012221 | Rhinitis, Allergic, Perennial |
| D065631 | Rhinitis, Allergic |
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D012130 | Respiratory Hypersensitivity |
Not provided
Not provided
| ID | Term |
|---|---|
| D011794 | Quercetin |
| C526219 | apple polyphenol extract |
| D017336 | Loratadine |
| C523187 | fluticasone furoate |
| ID | Term |
|---|---|
| D044948 | Flavonols |
| D005419 | Flavonoids |
| D002867 | Chromones |
| D001578 | Benzopyrans |
| D011714 |
Not provided
Not provided
4 group study
Not provided
Not provided
Department Biomedic and Science Universitas Sebelas Maret Surakarta Indonesia, Department Pharmacy Universitas Muhammadiyah Surakarta Indonesia, Universitas Sebelas Maret Hospital Sukoharjo Indonesia
Not provided
| Apple Extract | Other | In the treatment group is give of Apple extract |
|
| Loratadine 10 Mg | Other | Control Loratadine 10 mg/day |
|
| Fluticasone Furoate | Other | Control Fluticasone Furoate 27.5 mcg twice daily |
|
| Baseline, Month 3, and Month 6 |
| Nuclear Factor-Kappa Beta (NF-kB) Expression | Transcription factor expression by ELISA assay. | Baseline, Month 3, and Month 6 |
| Serum Interleukin-8 (IL-8) Levels | Concentration of IL-6 measured using Enzyme-Linked Immunosorbent Assay (ELISA). | Baseline, Month 3, and Month 6 |
| Serum TNF-alpha Levels | Concentration of TNF-alpha measured using Enzyme-Linked Immunosorbent Assay (ELISA). | Baseline, Month 3, and Month 6 |
Thank you and I hope this research can be used as a basis for additional therapy |
| D010038 |
| Otorhinolaryngologic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D003533 | Cyproheptadine |
| D003986 | Dibenzocycloheptenes |
| D001567 | Benzocycloheptenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D011083 | Polycyclic Compounds |